Semaglutide & frail heart failure patients | AI turns mammograms into CVD risk assessments | Regeneron gains a key FDA approval

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Thanks to AI, clinicians can use mammograms to do a lot more than identify signs of breast cancer. Researchers explored data from nearly 50,000 patients, presenting their findings in Heart.

Evinacumab-dgnb, sold by Regeneron under the brand name Evkeeza, can now be used to treat homozygous familial hypercholesterolemia in much younger patients.

The Department of Commerce is seeking more information about how current trade policies are impacting the U.S. medtech industry. The investigation could lead to the creation of new tariffs. Public comments are being accepted until Oct. 17, and the findings will be presented to President Donald Trump.

AI-powered chatbots can be valuable resources when users have questions about cardiovascular health—but they are still far from perfect.

The drug, already approved by the FDA to treat obstructive HCM, failed to outperform a placebo after 48 weeks.

Heart teams continue to play a major role at hospitals and health systems all over the world. Cardiac imagers who have trained in multiple modalities can provide those teams with a significant amount of value.

The FDA’s decision arrived just days after Apple announced the new feature. "This tool empowers patients and clinicians to work together, putting prevention at the center of care," one cardiologist told Cardiovascular Business. 

The balloon-free catheter, which already had a successful launch in the United States, has been associated with positive outcomes and the ability to reach certain lesions more accurately than balloon-based IVL platforms.

AI is only as effective as the data it was trained on, and many datasets lack diversity in terms of patient body mass index.

A new analysis is prompting questions regarding how rigorously many of the AI-enabled tools approved by the U.S. Food and Drug Administration are evaluated prior to their clearance.